Mepolizumab in hypereosinophilic syndrome: a systematic review and meta-analysis
Clinics; 76 (), 2021
We aimed to evaluate the efficacy and safety of mepolizumab (MEP) in the management of hypereosinophilic syndrome (HES). A systematic search was performed, and articles published until March 2021 were analyzed. The primary efficacy results evaluated were hospitalization rate related to HES, morbidity (ne...